Distribution of $bla_{CTX-M}$, $bla_{TEM}$, $bla_{SHV}$ and $bla_{OXA}$ genes in Extended-spectrum-β-lactamase-producing Clinical isolates: A three-year multi-center study from Lahore, Pakistan

Samyyia Abrar¹, Noor Ul Ain¹, Huma Liaqat¹, Shahida Hussain¹, Farhan Rasheed² and Saba Riaz¹,³*

Abstract

Background: Frequency of extended-spectrum-β-lactamase-producing clinical isolates is increasing worldwide. This is a multi-center study which was aimed to check the frequency of third-generation cephalosporin resistance and distribution of the key genetic determinants of Extended-spectrum-β-lactamase-producing Clinical isolates in Pakistan.

Methods: A total of 2372 samples were processed in three tertiary care hospitals and one diagnostic research center of Lahore, Pakistan during Aug-2014 to Sep-2017. Analytical profile index (API 20-E) was used for biochemical characterization of isolates. Antibiotic susceptibility testing (AST) and third generation cephalosporin resistant (3GC-R) isolates were subjected to: double disc synergism test (DDST), combination disc test (CDST) and epsilometric test (E-test) for confirmation of ESBL-production. PCR amplification of isolates with plasmid and genomic DNA was performed. Amplicon sequences were checked for gene-variants and statistical analyses were performed to check the significance of data.

Results: A total of 497/995 (50%) isolates including Escherichia coli 65% ($n=321$), Klebsiella spp. 25% ($n=124$) and Pseudomonas. 5% ($n=24$), Enterobacter spp. 4% ($n=20$) and Acinetobacter spp. 2% ($n=8$) were screened as third generation cephalosporin resistant (3GC-R). Urine 56% ($n=278$) followed by pus 20% ($n=99$) and wound swab 6% ($n=29$) were frequent sources. Incidence of ESBL-producers detected by combination disc test was 79% ($n=392$). PCR revealed $bla_{CTX-M}$ (76%) gene followed by $bla_{OXA}$ (52%), $bla_{TEM}$ (28%) and $bla_{SHV}$ (21%) were most prevalent among ESBL-producers detected by CDST. $bla_{CTX-M-1}$ (65%), $bla_{OXA}$ (78%) and $bla_{TEM}$ (57%) genes were carried on plasmids. Amplicon sequencing revealed $bla_{CTX-M-15}$ (75%), $bla_{OXA-1}$ (49%) and $bla_{TEM-1}$ (49%) and 21 ($n=28$) isolates carried three genes in them.

Conclusion: Prevalence of ESBL-producing isolates has increased 1.13 folds during study years. Isolates had high prevalence of ESBL-encoding $bla_{CTX-M-15}$ gene and narrow spectrum $bla_{OXA-1}$ and $bla_{TEM-1}$ were also prevalent.

Keywords: AST, Multiplex PCR, ESBL, Phenotypic test, Molecular tests, Pakistan

* Correspondence: saba.mmg@pu.edu.pk
¹Department of Microbiology and Molecular genetics, University of the Punjab, Lahore, Pakistan
²Citilab and Research Center, Lahore, Pakistan
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Multidrug resistant clinical isolates have important clinical consequence in community and hospital settings [1]. They have evolved as a global concern, exacerbated by under reporting in some regions of the world [2]. The tendency of these isolates concurrently resistant to other groups of antibiotics significantly limits the selection of antibiotics for treatment of infections [3]. The development of resistance for third generation cephalosporin is attributed to production of β-lactamases including extended-spectrum-β-lactamases (ESBLs), AmpCs and carbapenemases [4]. The most significant β-lactamase genes are variants of CTX-M, SHV, TEM, VEB, GES, PER, TLA and OXA which have broadened the substrate specificity against ceftazidime, cefotaxime and ceftriaxone [4, 5]. These genes have broad host range but predominantly found in Escherichia coli and Klebsiella spp. [6]. While, OXA genes are found predominantly in Pseudomonas spp. and Acinetobacter spp. [7]. Moreover, many clinical pathogens harbor more than one β-lactam genes [8]. Plasmid association of these genes makes them easily spreadable. Due to the diversity of these enzymes, multiplex-PCR based detection methods have become a widely used tool for epidemiological surveys [8–10].

Asian countries are highly affected by extended spectrum-β-lactamase-producers inducing multidrug-resistant phenotype [11–14]. Several studies have reported the community-association of ESBL-producers [11, 14, 15]. In Pakistan, an increase in the number of ESBL-associated infections has been observed in last few decades [16–21]. Lack of regular surveillance programs at national or international levels, inadequate infection control agencies, lack of facilities and inappropriate diagnostic approaches contribute to the emergence of the antibiotic resistance in bacteria [2, 10, 22]. Moreover, dissemination of these isolates in the community demands the urgent call for surveillance of resistance and molecular characterization for extended-spectrum-β-lactamase-producers [23]. This study was designed to check molecular epidemiology of blaCTX-Ab, blatem, blashv and blaoxa genes among ESBL-producers in Pakistani population to have a generalized view about the situation in our region.

Materials and Methods
Study design
This cross-sectional study was conducted at the Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore in collaboration with the Department of Pathology, Allama Iqbal Medical College/ Jinnah Hospital, Lahore, Punjab Institute of Cardiology (PIC), Lahore, Doctors hospital, Lahore and Citilab and Research center, Lahore from August 2014 to September 2017. This study was approved by the ethical review board of the Citilab and Research Center, Lahore under reference: 28th-18 CLRC/ 28th.

Bacterial Isolates
A total of 2,372 samples were processed during study period; 77% (n=1835) cultures were positive and 54% (n=995) gram negative non-duplicate clinical isolates from various sources were collected by standard culturing methods. Antibiotic susceptibility testing (AST) was performed according to the guidelines provided by clinical laboratory standards institute [24] by using standard antibiotic discs as mentioned in our previous study [16]. Multiple antibiotics resistance (MAR) value was calculated as reported before [25]. E. coli ATCC 25922 was used as positive control and K. pneumoniae ATCC 700603 was used as negative control [26]. Analytical profile index (API 20-E) was used for biochemical characterization of isolates resistant to third generation cephalosporins.

Phenotypic confirmation of ESBL-producers
Third generation cephalosporin resistant (3GC-R) isolates as screened by Antibiotic susceptibility test (AST) were subjected to: double disc synergism test (DDST), combination disc test (CDST) and epsilometric test (E-test) for confirmation of ESBL-production [24]. In DDST, amoxicillin (AMC 20/10μg), cefuroxime (CRO 30μg), ceftazidime (CAZ 30μg) and cefotaxime (CTX 30μg) were applied [27]. In CDST, CAZ (30μg) and CTX (30μg) alone and in combination with clavulanic acid (CTC (40μg) and CZC (40μg) were used [16]. All discs used were from Oxoid, Inc (Canada). For E-test, CTX / CTX+ and CAZ/CAZ+ strips from AB BIODISK MICTM were used [24].

Molecular detection
The DNA used for multiplex-PCR was extracted by the heat lysis method [16]. In Multiplex-PCR, 2 μl whole cell lysate DNA for each isolate was used separately in 25 μl PCR-master mix and amplification primers as previously mentioned [16, 28, 29]. PCR amplification conditions were: Initial step of denaturation at 95°C for 5 min followed by 35 cycles of denaturation at 95°C for 1 min then annealing at 56°C for 1.5 min, extension at 95°C for 1 min and the final extension was done at 95°C for 10 min (Table 1).

Amplicon sequencing and in-silico analysis
PCR amplified products were sequenced by Advance Bioscience International, Pakistan in collaboration with 1st Base, Malaysia [30]. Nucleotide sequence similarity searches were performed using the services of National Centre for Biotechnology Information (NCBI) (https://blast.ncbi.nlm.nih.gov/Blast.cgi), BLAST, CLUSTALX, and MEGA 7.0 software were used for sequence
alignment of amplicon sequences obtained with already submitted sequences of bla<sub>CTX-M-6</sub>, bla<sub>TEM</sub>, bla<sub>SHV</sub> and bla<sub>OXA</sub> in GenBank.

### Statistical Analysis

All statistical analyses were performed using IBM-SPSS statistics 23. Bivariate analyses were performed using chi-square test for categorical variables. All p-values were two sided. The percentage values included in this article are the “valid percentages,” which exclude the missing data.

### Results

#### Demographic data and distribution of clinical isolates

A total of 50% (n=497/995) third generation cephalosporin resistant (3GC-R) clinical isolates were found among 995 gram-negative isolates. These include 65% (n=321) *Escherichia coli*, 25% (n=124) *Klebsiella pneumoniae*, 5% (n=24) *Pseudomonas aeruginosa* and 4% (n=20) were *Enterobacter* spp. and small number of *Acinetobacter* spp. 2% (n=8) were found. These isolates were obtained from urine 59% (n=278), pus 20% (n=99), wound swab 6% (n=29), Foley's tip 3% (n=17), sputum 3% (n=16), tracheal secretion 3% (n=14), body fluids 2% (n=10), blood 8% (n=40) and HVS 1% (n=4) respectively with p-value <0.0001. Among study population, significantly (p-value <0.0001) higher number of strains were isolated from males 53% (n=265) compared to females 47% (n=232). Age group 41-60 years was prevalent 35% (n=174) followed by 21-40 years 29% (n=146) (p-value <0.0001) (Table 2).

#### Phenotypic screening and confirmation of ESBL-producers

Isolates had high resistance towards β-lactams including cefotaxime and cefaclor 100% (n=497). While 98.6% (n=490) and 96.4% (n=479) isolates were resistant for cefuroxime and ceftazidime respectively. While, resistance for carbapenems was low 11% (n=55). Moderate to high resistance towards aminoglycosides (67–89%) and quinolones (74–82%) was seen except amikacin 14% (n=70). While isolates were quite susceptible to ceftazidime/ceftriaxone 6% (n=30) and pipercillin/tazobactam 24% (n=119). 60% (n=303) of isolates had MAR-value in the range of 0.60 to 0.799, while 27% (n=136) were having MAR-value of 0.8–1.0. Rest of the isolates 14% (n=57) had MAR-value of 0.2–0.5. ESBL-positivity was as follows; double disc synergy test 55% (n=273), combination disc test 79% (n=392) and discsensitivity was as follows; double disc synergy test 55% (n=273), combination disc test 79% (n=392) and epsilometric-test showed 58% (n=288). Year-wise data indicated frequency of ESBL-producers among 3GC-R has increased from 76% (n=102) to 88% (n=146) during study years (Table 2). *E. coli* 75% (n=241), *K. pneumoniae* 80% (n=99), *Pseudomonas* spp. 72% (n=15) and *Enterobacter* spp. 75% (n=15) had ceftaxime/ceftazidime+ MIC > 32/0.064 = 500 while 5.6% (n=28) remained non-determined. Cefotaxime/cefotaxime+ > 16/0.016 = 1000 was most frequent MIC with *E. coli* 64% (n=206), *K. pneumoniae* 69% (n=85), *Pseudomonas* spp. 63% (n=15), while 6% (n=30) remained non-determined by cefotaxime/cefotaxime+ (Table 3).

Association analysis indicated among 82% (n=262) ESBL-positive *E. coli*, females were more prone to such infection with 53% (n=138). While, infectivity rate was high for males with ESBL-positive *Klebsiella pneumoniae* 54% (n=47) and *Enterobacter* spp. 57% (n=8) (Tables 4 and 5). High frequency of ESBL-producers 36% (n=140) came from age group of 41–60 years. Age associated ESBL-infectivity rate was more confined to age group 41–60 years in *E. coli* 36% (n=94), *Klebsiella* spp. 38% (n=35) and *Pseudomonas* spp. 33% (n=8) (Table 6). Urine samples were frequent source of ESBL-phenotype among *E. coli* 65% (n=171), *Klebsiella* spp. 39% (n=35) and *Pseudomonas* spp. 38% (n=9) (Table 5).

#### Molecular detection

After screening, ESBL-producing isolates (n=392) as detected by combination disc test were processed for the

### Table 1 Primer sequences and amplification conditions used in this study

| Target gene | Primer name | Sequence | Annealing temp (°C) | Product size (bps) | References |
|-------------|-------------|----------|---------------------|-------------------|------------|
| bla<sub>CTX-M-1</sub> | CTXM1-F | GACGATGTCACTGGCTGAGC | 55 | 500 | [8] |
| bla<sub>CTX-M-1</sub> | CTXM1-R | AGCCGCCGACGCCTATTACA | 55 | 300 | [8] |
| bla<sub>CTX-M-3</sub> | CTXM825F | CGCTTTGCGATGGGAGACC | 55 | 392 | [9] |
| bla<sub>CTX-M-3</sub> | CTXM825R | GCTCAGTACGATCGAGCC | 56 | 392 | [9] |
| bla<sub>SHV</sub> | SHV-F | AGGATTGACTGCTTTTGT | 56 | 392 | [9] |
| bla<sub>SHV</sub> | SHV-R | ATTTGCTGATTTCGCTCG | 56 | 392 | [9] |
| bla<sub>TEM</sub> | TEM-C | ATCGCAATAAACCAGC | 56 | 392 | [9] |
| bla<sub>TEM</sub> | TEM-H | CCCGGAAGAATTTC | 56 | 392 | [9] |
| bla<sub>OXA</sub> | OXA-F | ATATCTCTAGTGTCATCTCC | 56 | 619 | [9] |
| bla<sub>OXA</sub> | OXA-R | AAACCCTTAACCATCC | 56 | 619 | [9] |
Table 2 Distribution of isolates according to different parameters from 2014 to 2017

| Parameters                      | Study year | 2014 | 2015 | 2016 | 2017 | 2014–2017 | Chi-score | p-value |
|---------------------------------|------------|------|------|------|------|-----------|-----------|---------|
| Initial screening               |            |      |      |      |      |           |           |         |
| Samples Processed               |            | 400  |  500 |  500 |  435 |   1835    |    9.33   | 0.0023  |
| Strains Screened                |            | 230  |  230 |  230 |  250 |    995    |    1.91   | 0.1671  |
| 3GC-R*                          |            | 134  |   85 |   85 |  166 |    497    |   30.05   | <0.0001 |
| Third generation cephalosporin resistant isolates | |      |      |      |      |           |           |         |
| Klebsiella spp.                 |            | 22   |  32  |  45  |  25  |    124    |   31.19   | <0.0001 |
| Escherichia coli                |            | 106  |  41  |  40  |  134 |    321    |   21.99   | 0.0012  |
| Enterobacter spp.               |            | 6    |  12  |   0  |  2   |     20    |   15.95   | 0.0140  |
| Pseudomonas spp.                |            | 0    |  24  |   0  |   0  |     24    |   74.48   | <0.0001 |
| Acinetobacter spp.              |            | 0    |   3  |   0  |   5  |     8     |    4.32   | 0.6335  |
| Demographic Data                |            |      |      |      |      |           |           |         |
| Gender based distribution       |            |      |      |      |      |           |           |         |
| Male                            |            | 69   |  47  |  47  | 102  |    265    |   11.52   | 0.0342  |
| Female                          |            | 65   |  65  |  38  |  64  |    232    |    7.98   | 0.7867  |
| Age wise distribution           |            |      |      |      |      |           |           |         |
| <1–20                           |            | 17   |  27  |  14  |  10  |     68    |   32.19   | 0.0013  |
| 21–40                           |            | 33   |  26  |  40  |  47  |    146    |   60.29   | <0.0001 |
| 41–60                           |            | 45   |  41  |  27  |  61  |    174    |   58.53   | <0.0001 |
| 61–80                           |            | 39   |  15  |  4   |  47  |    105    |   53.13   | <0.0001 |
| >80                             |            | 0    |   3  |   0  |   1  |     4     |    7.98   | 0.7867  |
| Sample source                   |            |      |      |      |      |           |           |         |
| Urine                           |            | 80   | 150  | 26   | 16  |     272   |   18.93   | 0.0003  |
| Blood                           |            | 5    |   11 |   5  | 12   |     33    |    27.4   | <0.0001 |
| Pus                             |            | 40   |  33  |  18  |  7   |     98    |    9.74   | 0.0209  |
| Wound                           |            | 2    |  17  |  11  |  13  |     43    |    29.26  | <0.0001 |
| Tissue                          |            | 2    |  0   |  1   |  0   |     3     |    3.75   | 0.2898  |
| Sputum                          |            | 3    |   1  | 12   |  0   |     16    |    38.79  | <0.0001 |
| Tips                            |            | 1    |  0   |  2   |  0   |     3     |    6.11   | 0.1116  |
| Secretions                      |            | 0    |   4  |  8   |  0   |     12    |    22.12  | <0.0001 |
| Fluid                           |            | 3    |   7  |  0   |  0   |     10    |    4.02   | 0.2540  |
| High vaginal swab               |            | 2    |  2   |  2   |  0   |     6     |    1.77   | 0.6215  |
| Washings                        |            | 0    |  1   |  0   |  0   |     1     |    1.2    | 0.731   |
| Phenotypic detection tests      |            |      |      |      |      |           |           |         |
| Phenotypic test                 |            |      |      |      |      |           |           |         |
| ASTb                            |            | 134  |  112 |  85  | 166  |    497    |    1.45   | 0.9975  |
| CDSTc                           |            | 102  |  65  |  85  | 147  |    399    |    20.8   | 0.0136  |
| DDSTd                           |            | 95   |  89  |  18  |  71  |    273    |   32.19   | 0.0002  |
| E-teste                         |            | 74   |  84  |  37  | 108  |    303    |    5.36   | 0.8019  |

Percentages are mentioned in parenthesis
*Third generation cephalosporin resistant
*Antibiotic susceptibility testing
*Combination disc test
*Double disc synergy test
*Epsilometric test
 detection of $bla_{CTX-M}$, $bla_{SHV}$, $bla_{TEM}$ and $bla_{OXA}$ encoding genes by PCR. In Singleplex-PCR, $bla_{CTX-M}$ genes were predominant 76% ($n = 303$) followed by $bla_{OXA}$ 52% ($n = 203$), $bla_{TEM}$ 28% ($n = 109$) and $bla_{SHV}$ 21% ($n = 82$). Multiplex-PCR showed that $bla_{CTX-M/SHV/TEM/OXA}$ and $bla_{OXA/TEM/SHV}$ gene combination was present in 9% ($n = 36$) and 11% ($n = 43$) respectively, $bla_{TEM/SHV}$ and $bla_{TEM/OXA}$ combination was present in 13% ($n = 51$) and 27% ($n = 105$) respectively (Table 7, Fig. 1).

Amplion sequencing and subsequent analysis indicated $bla_{CTX-M-15}$ 86% ($n = 260$) was prevalent among $bla_{CTX-M-1}$ group. $bla_{OXA-1}$ 49% ($n = 99$) were found among $bla_{SHV}$ amplicons and $bla_{TEM-1B}$ 63% ($n = 69$). 83% ($n = 190$) of $E. coli$ had $bla_{CTX-M-15}$ followed by $bla_{SHV-1}$ 55% ($n = 69$) and $bla_{TEM-1B}$ 33% ($n = 76$). $Klebsiella$ spp. contained $bla_{CTX-M-15}$ 67% ($n = 36$) followed by $bla_{SHV-11}$ 89% ($n = 47$) and $bla_{TEM-1B}$ 34% ($n = 19$). While, $Pseudomonas$ spp. and $Acinetobacter baumannii$ had variants of $OXA$ ($bla_{OXA-50}$, $bla_{OXA-144}$, $bla_{OXA-23}$, $bla_{OXA-371}$, $bla_{OXA-58}$, $bla_{OXA-68}$ and $bla_{OXA-94}$) (Table 8).

**Discussion**

Extensive use of antibiotics has resulted in resistance against variety of antibiotics including cephalosporins. They affect countries all over the world but control and prevention of ESBL-producers is severely compromised in underdeveloped countries [31–33].

Here, high prevalence of third generation cephalosporin resistant isolates (50%) was observed which has subsequently increased by 1.13-fold from 2014 to 2017. This high resistance also indicates high selection pressure for third generation cephalosporin resistant isolates [34]. This increase of resistance is worrisome as we are left with few treatment options including cephalosporins. Widespread usage of antibiotics might be the

**Table 3** Minimum Inhibitory Concentration (MIC) of applied antibiotics along with clavulanic acid

| MIC ratio | $> 32/0.064 = 500$ | $> 32/0.125 = 256$ | $> 32/0.19 = 126$ | $16/0.38 = 42.1$ | $4/0.25 = 16$ |
|-----------|-------------------|-------------------|-------------------|-----------------|-----------------|
| E. coli ($n = 321$) | 13 (4%) | 241 (75%) | 39 (12%) | 19 (6%) | 3 (1%) |
| Klebsiella spp. ($n = 124$) | 2 (1.8%) | 99 (80%) | 10 (8.3%) | 6 (4.6%) | 7 (5.5%) |
| Pseudomonas spp. ($n = 24$) | 5 (21%) | 17 (72%) | 2 (8.3%) | 0 (0%) | 0 (0%) |
| Enterobacter spp. ($n = 20$) | 2 (10%) | 15 (75%) | 2 (10%) | 0 (0%) | 1 (5%) |
| Acinetobacter spp. ($n = 8$) | 6 (75%) | 2 (25%) | 0 (0%) | 0 (0%) | 0 (0%) |

**Table 4** Gender based association of infectivity among different isolates

| Isolates | Gender | Number (%) | ESB production | Chi-score | Odds ratio |
|-----------|--------|------------|----------------|-----------|------------|
| E. coli ($n = 321$) | Male | 152 (47) | 124 (82) | 28 (18) | 1.834996 | 1.0317 (0.5834–1.8245) |
| | Female | 169 (53) | 138 (82) | 31 (18) | 0.9146 |
| Klebsiella spp. ($n = 124$) | Male | 68 (55) | 49 (72) | 19 (28) | 4.08124 | 0.989 (0.4502–2.1746) |
| | Female | 56 (45) | 40 (71) | 16 (29) | 0.919 |
| Pseudomonas spp. ($n = 24$) | Male | 13 (54) | 10 (77) | 3 (23) | 0.094083 | 0.3333 (0.0294–3.775) |
| | Female | 11 (46) | 10 (91) | 1 (9) | 0.375 |
| Enterobacter spp. ($n = 20$) | Male | 12 (60) | 8 (67) | 4 (33) | 1.123626 | 0.6667 (0.0902–4.9281) |
| | Female | 8 (40) | 6 (75) | 2 (25) | 0.6912 |
| Acinetobacter spp. ($n = 8$) | Male | 3 (38) | 2 (67) | 1 (23) | 0.337912 | 0.4000 (0.0160–10.0173) |
| | Female | 5 (62) | 5 (100) | 0 (0) | 0.5771 |
factor of such increase in resistance in our hospital settings [16, 35].

*Escherichia coli* had high 3GC-R burden compared to *Klebsiella* spp. and *Enterobacter* spp. Bari et al., reported similar findings in a study conducted in 2013 in Lady Reading Hospital Peshawar [36]. These results are comparable to findings in Tanzania where 45% ESBL-producers have been reported [37]. Similar findings from different regions of the world were observed as previously studied [38, 39]. Nahid et al., reported very high prevalence of ESBL-producers (87.5%) but this is because she worked on Metallo-β-lactamase producers which are highly resistant organisms [40].

ESBL infectivity rate in males was moderately high as compared to females. This rate is quite similar to the rate reported by Afirdi et al. [41]. In our study ESBL infections were significantly higher in the mean age group of 41-60 years whereas, high infection rates have been reported in old age individuals who are immuno-compromised and hence, more prone to infections [42]. We have found isolates originating from females were more frequent ESBL-producers. According to many reports males have significantly higher rates of hospital-acquired infection and community-acquired infections are more prevalent in females [42–46]. These findings represent that males are more

| Table 5 Age-wise association of ESBL-production with different isolates |
|-----------------------------------------------|--------------------|-----------------|-----------------|--------------------|-----------------|-----------------|
| Isolates                                      | Age                | Number (%)        | ESBL-production  | Chi-score | p-value |
|                                               | group              |                  | Positive (%)     | Negative (%) |                  |
| *Escherichia coli* (n = 321)                  | 0–20               | 44 (14)           | 41 (93)          | 3 (7)      | 0.000678         |
|                                               | 21–40              | 100 (31)          | 82 (82)          | 18 (3)     | 0.767442         |
|                                               | 41–60              | 120 (37)          | 94 (78)          | 26 (3)     | 0.045746         |
|                                               | 61–80              | 53 (17)           | 45 (85)          | 8 (6)      | 1.40471          |
|                                               | > 80               | 4 (1)             | 0 (0)            | 4 (75)     | 14.3333          |
| *Klebsiella* spp. (n = 124)                   | 0–20               | 22 (18)           | 18 (82)          | 4 (18)     | 0.170543         |
|                                               | 21–40              | 38 (31)           | 28 (74)          | 10 (26)    | 0.450632         |
|                                               | 41–60              | 46 (37)           | 35 (76)          | 11 (24)    | 0.118343         |
|                                               | 61–80              | 17 (14)           | 10 (59)          | 7 (41)     | 3.734724         |
|                                               | > 81               | 1 (1)             | 1 (100)          | 0 (0)      | 0.27907          |
| *Pseudomonas* spp. (n = 24)                   | 0–20               | 6 (25)            | 5 (83)           | 1 (17)     | 0.093346         |
|                                               | 21–40              | 5 (21)            | 4 (80)           | 1 (20)     | 0.00969          |
|                                               | 41–60              | 10 (42)           | 8 (80)           | 2 (20)     | 0.01938          |
|                                               | 61–80              | 3 (13)            | 3 (100)          | 0 (0)      | 0.837209         |
|                                               | > 81               | 0 (0)             | 0 (0)            | 0 (0)      |                 |
| *Enterobacter* spp. (n = 20)                  | 0–20               | 5 (25)            | 4 (80)           | 1 (25)     | 0.00969          |
|                                               | 21–40              | 5 (25)            | 3 (60)           | 2 (67)     | 0.968992         |
|                                               | 41–60              | 5 (25)            | 2 (40)           | 3 (150)    | 4.273256         |
|                                               | 61–80              | 5 (25)            | 5 (100)          | 0 (0)      | 1.395349         |
|                                               | > 81               | 0 (0)             | 0 (0)            | 0 (0)      |                 |
| *Acinetobacter* spp. (n = 8)                  | 0–20               | 1 (13)            | 0 (0)            | 1 (13)     | 3.583333         |
|                                               | 21–40              | 3 (38)            | 1 (13)           | 2 (25)     | 3.537468         |
|                                               | 41–60              | 1 (13)            | 1 (13)           | 0 (0)      | 0.27907          |
|                                               | 61–80              | 2 (25)            | 1 (13)           | 1 (13)     | 0.931202         |
|                                               | > 81               | 1 (13)            | 1 (13)           | 0 (0)      | 0.27907          |

*only p-values <0.05 are shown*

| Table 6 Association of ESBL-production with type of isolates under investigation |
|-----------------------------------------------|-----------------|--------------------|-----------------|--------------------|
| Isolates                                      | Total number (%) | ESBL-production  | Chi-score | p-value |
|                                               |                 | Positive (%)     | Negative (%) |                  |
| *Escherichia coli*                            | 321 (65)        | 262 (82)         | 59 (18)     | 6.792369985 .00951 |
| *Klebsiella* spp.                             | 124 (25)        | 89 (72)          | 35 (28)     |                  |
| *Pseudomonas* spp.                            | 24 (5)          | 20 (83)          | 4 (17)      |                  |
| *Enterobacter* spp.                           | 20 (4)          | 14 (70)          | 6 (30)      |                  |
| *Acinetobacter* spp.                          | 8 (2)           | 7 (88)           | 1 (13)      |                  |
often exposed to the hospital settings compared to the females.

Studies indicated prevalence of ESBL-producers is variable in different regions of world as detected by phenotypic detection tests [47–50]. DDST determined only 54 % strains as ESBL-producers while CDST determined 79 % as ESBL-producers. Ejaz et al., reported similar detection efficiency of CDST as we reported here [17]. Prevalence of ESBL-producing isolates is quite higher than from other parts of the world including India (42.3 %), Bangladesh (37.8 %). Dalela et al., reported 90 % sensitivity of CDST for the detection of ESBL-producers [51]. E-test revealed that 61 % strains were ESBL-producers while 39 % remained non-determined by this technique. Mohanty et al. also reported 61 % positivity rate for ESBL-producers by E-test technique [52]. Such discrepancies between susceptibility data and phenotypic test results have increased the demand for more sensitive methods of ESBL-producer detection for implementation into routine susceptibility testing procedures. Despite of high resistance burden of ESBL-producers, the usage of molecular detection methods is not very common. A recent meta-analysis describes only 11% studies that reported PCR-based detection methods for screening of ESBL-producers in Pakistan [20]. Lack of knowledge and technical staff triggers the use of PCR-based methods as it is the rapid and reliable method of ESBL-producer detection [8]. It seems that blaCTX-M is predominant genotype in this region of the world. Another study from Pakistan indicated 72% of isolates had blaCTX-M gene which was lower than prevalence of blaCTX-M gene found in this study [16]. Few studies from other parts of world have shown different prevalence of blaCTX-M gene

| Sample               | Number (%) | ESBL-production | Chi-score | p-value  |
|----------------------|------------|-----------------|-----------|----------|
| (N = 497)            |            | Positive (%)    | Negative (%) |          |
| Urine                | 271 (55)   | 221 (82)        | 50 (18)   | 19.50840541 | <0.0001  |
| Pus                  | 97 (20)    | 73 (75)         | 24 (25)   |          |
| Wound Swab           | 39 (8)     | 33 (85)         | 6 (15)    |          |
| Fluids and secretions| 24 (5)     | 16 (67)         | 8 (33)    |          |
| Catheters and tips   | 17 (3)     | 11 (65)         | 6 (35)    |          |
| Blood                | 18 (4)     | 10 (56)         | 8 (44)    |          |
| Sputum               | 16 (3)     | 16 (100)        | 0 (0)     |          |
| High Vaginal Swab    | 7 (2)      | 6 (88)          | 1 (12)    |          |
| Others               | 6 (1)      | 6 (100)         | 0 (0)     |          |
among isolates including 84.7% (Chile), 98.8% (China) and 13.6% (Tanzania) [53–55]. We observed \textit{bla}_{\text{TEM}} and \textit{bla}_{\text{OXA}} genes were less common in our settings with 50% prevalence. Report from Hamad Medical Corporation, Qatar stated that CTX-M group has evolved through mutations in \textit{bla}_{\text{TEM}} and \textit{bla}_{\text{SHV}} genes and is recent endemic [56].

\textit{Acinetobacter baumannii} isolates had OXA variants (\textit{bla}_{\text{OXA}} = 23,58 and others) which are carbapenemase-encoding genes [57]. These variants have previously been isolated from France, Spain and Turkey which indicates the global spread [50]. \textit{bla}_{\text{OXA}} = 23 was amplified from pan-drug resistance \textit{A. baumannii} only which is in accordance with our results [58]. But these \textit{Acinetobacter baumannii} isolates did not carry any of the ESBL-encoding genes which terminate the co-existence of carbapenemase and ESBL-encoding genes. This is in accordance with already published article which states no significant relation between both groups [59]. Appearance of different variants might provide extra advantage for these isolates to spread them and complicate the therapeutics.

With the passage of time increase in co-resistance of different ESBL-producing genes is worrisome as co-existence of multiple genes hinders the detection of ESBL-producers and complicates the treatment strategy for clinicians. Moreover, high plasmid burden was found these plasmids are involved in gene-transfer and they also carry additional antibiotic resistance genes along with \textit{\beta}-lactam antibiotics.

\begin{table}[h]
\centering
\begin{tabular}{lcccccccc}
\hline
Gene variant & Total & \textit{Escherichia coli} \((n = 321)\) & \textit{Klebsiella pneumoniae} \((n = 124)\) & \textit{Enterobacter cloacae} \((n = 20)\) & \textit{Pseudomonas aeruginosa} \((n = 24)\) & \textit{Acinetobacter baumannii} \((n = 8)\) & Chi-score & *p-value \\
\hline
\textit{bla}_{\text{CTXM-1}} & 303 (76) & 238 (74) & 53 (43) & 5 (25) & 7 (29) & 0 (0) & 13.2333292 & <0.0001 \\
\textit{bla}_{\text{CTX-M-15}} & 260 (86) & 204 (98) & 48 (91) & 3 (50) & 5 (71) & 0 (0) & 6.33967046 & 0.0118 \\
\textit{bla}_{\text{OXA}} & 203 (52) & 126 (39) & 35 (28) & 15 (75) & 19 (79) & 8 (100) & 11.31364661 & <0.0001 \\
\textit{bla}_{\text{OXA-1}} & 99 (49) & 69 (55) & 0 (0) & 7 (50) & 0 (0) & 0 (0) & 4.800612279 & 0.0284 \\
\textit{bla}_{\text{OXA-50}} & 7 (3) & 0 (0) & 0 (0) & 7 (100) & 0 (0) & 0 (0) & 3.997740394 & 0.0456 \\
\textit{bla}_{\text{OXA-144}} & 2 (1) & 0 (0) & 0 (0) & 0 (0) & 0 (0) & 2 (25) & 32.84026642 & <0.0001 \\
\textit{bla}_{\text{OXA-23}} & 4 (2) & 0 (0) & 0 (0) & 0 (0) & 0 (0) & 4 (50) & 65.68053525 & <0.0001 \\
\textit{bla}_{\text{OXA-371}} & 2 (1) & 0 (0) & 0 (0) & 0 (0) & 0 (0) & 2 (25) & 32.84026642 & <0.0001 \\
\textit{bla}_{\text{OXA-58}} & 2 (1) & 0 (0) & 0 (0) & 0 (0) & 0 (0) & 2 (25) & 32.84026642 & <0.0001 \\
\textit{bla}_{\text{OXA-68}} & 2 (1) & 0 (0) & 0 (0) & 0 (0) & 0 (0) & 2 (25) & 32.84026642 & <0.0001 \\
\textit{bla}_{\text{OXA-94}} & 2 (1) & 0 (0) & 0 (0) & 0 (0) & 0 (0) & 2 (25) & 32.84026642 & <0.0001 \\
\textit{bla}_{\text{TEM}} & 109 (28) & 82 (29) & 23 (19) & 4 (20) & 0 (0) & 0 (0) & 16.56736583 & <0.0001 \\
\textit{bla}_{\text{TEM-1B}} & 69 (34) & 76 (33) & 19 (83) & 1 (25) & 0 (0) & 0 (0) & 1.942065018 & 0.1492 \\
\textit{bla}_{\text{SHV}} & 82 (21) & 10 (3) & 65 (52) & 7 (35) & 0 (0) & 0 (0) & 13.5652163 & <0.0001 \\
\textit{bla}_{\text{SHV-10}} & 5 (6) & 1 (10) & 4 (8) & 0 (0) & 0 (0) & 0 (0) & 5.56456898 & 0.0183 \\
\textit{bla}_{\text{SHV-11}} & 47 (57) & 0 (0) & 47 (89) & 0 (0) & 0 (0) & 0 (0) & 22.6584202 & <0.0001 \\
\textit{bla}_{\text{SHV-1}} & 13 (16) & 0 (0) & 13 (25) & 0 (0) & 0 (0) & 0 (0) & 16.9937791 & <0.0001 \\
\textit{bla}_{\text{SHV-27}} & 4 (5) & 0 (0) & 4 (8) & 0 (0) & 0 (0) & 0 (0) & 5.56456898 & 0.0183 \\
\textit{bla}_{\text{SHV-28}} & 4 (5) & 0 (0) & 4 (8) & 0 (0) & 0 (0) & 0 (0) & 5.56456898 & 0.0183 \\
\textit{bla}_{\text{SHV-83}} & 24 (29) & 0 (0) & 24 (45) & 0 (0) & 0 (0) & 0 (0) & 5.56456898 & 0.0183 \\
\hline
Gene combinations & & & & & & & & \\
\textit{bla}_{\text{CTXM-15}} + \textit{bla}_{\text{OXA-1}} & 71 (14) & 55 (60) & 5 (42) & 2 (10) & 0 (0) & 0 (0) & 5.44065331 & 0.0197 \\
\textit{bla}_{\text{OXA-1}} + \textit{bla}_{\text{TEM-1B}} & 30 (6) & 22 (20) & 6 (50) & 1 (5) & 0 (0) & 1 (13) & 0.485769791 & 0.485769791 \\
\textit{bla}_{\text{CTX-M-15}} + \textit{bla}_{\text{TEM-1B}} & 44 (9) & 33 (7) & 10 (8) & 0 (0) & 0 (0) & 1 (13) & 1.009389671 & 0.0001 \\
\textit{bla}_{\text{CTXM-15}} + \textit{bla}_{\text{SHV-11}} & 4 (3) & 0 (0) & 4 (33) & 0 (0) & 0 (0) & 0 (0) & 19.46666667 & <0.0001 \\
\textit{bla}_{\text{CTXM-15}} + \textit{bla}_{\text{OXA-1}} + \textit{bla}_{\text{TEM-1B}} & 28 (4) & 22 (7) & 5 (4) & 0 (0) & 0 (0) & 1 (25) & 0.234071093 & \\
\hline
\end{tabular}
\caption{Gene variants obtained by amplicon sequencing in different isolates}
\end{table}

*only p-values <0.05 are shown
Conclusions and Recommendations

In conclusion, blaCTX-M-15 type ESBL-producing genes and blaOXA-type narrow spectrum β-lactamases are prevalent among the isolates in our health care settings. Isolates had high resistance towards cephalosporins. Resistance towards cephalosporins and carbapenems has increased many folds during study period. Co-expression of multiple genes complicates the treatment strategy. blaCTX-M-15 a pandemic genotype is quite prevalent and their plasmid association is a big thread for the community. There is a dire need for efficient molecular diagnostic tools for the detection of bla genes at laboratory level.

Abbreviations
CDST: Combination disc test; DDST: Double disc synergy test; ESBL: Extended-spectrum β-lactamases; ESBLs: Extended-spectrum-β-lactamase-producing strains; E-Test: Epsilometric test; MAR: Multiple-antibiotics resistance; MIC: Minimum inhibitory concentration

Acknowledgements
We would like to pay our gratitude towards Microbiology section of Allama Iqbal Medical College/Jinnah Hospital, Lahore, Punjab Institute of cardiology (PIC), Doctors hospital, Lahore and Citilab and Research Center, Lahore to provide assistance in collection of bacterial isolates.

Funding
No funding was provided for this study

Availability of data and materials
All the data files generated during this study are with authors of this and can be provided on demand.

Authors' contributions
Study concept and design of the study: SR; data collection: (SA and HL); FR, CA, AR and SH. All authors approved the final version of manuscript.

Ethics approval and consent to participate
The study was approved by local ethics committee (CitiLab and Research Centre Ref # 28th -18 CLRC/ 28th).

Consent for publication
Not applicable

Competing interests
This study is part of PhD thesis of Ms. Sarnyia Abrar. All other authors declare that the work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Microbiology and Molecular genetics, University of the Punjab, Lahore, Pakistan. 2Allama Iqbal Medical College, Jinnah Hospital Lahore, Lahore, Pakistan. 3Citilab and Research Center, Lahore, Pakistan.

Received: 18 March 2019 Accepted: 9 May 2019

Published online: 22 May 2019

References
1. O’Connell N, Keating D, Kavanagh J, Schaffer K. Detection and characterization of extended-spectrum beta-lactamase-producing Enterobacteriaceae in high-risk patients in an Irish tertiary care hospital. J Hosp Infect. 2015;90(2):102–7.
2. Molton JS, Tambyah PA, Ang BS, Ling ML, Fisher DA. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. Clin Infect Dis. 2013;56(9):1310–8.
3. Rudresh S, Nagaratnamma T. Extended spectrum β-lactamase producing Enterobacteriaceae & antibiotic co-resistance. Indian J Med Res. 2011;133(1):116.
4. Pfeffer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol. 2010;300(6):371–9.
5. Otero J, Navarro C, Cerenciano E, Delgado-Iribarren A, Wilhelm I, Orden B, et al. Spread of Escherichia coli strains with high-level cefotaxime and cefazolin resistance between the community, long-term care facilities, and hospital institutions. J Clin Microbiol. 2006;44(7):2359–66.
6. Bajpai T, Pandey M, Varma M, Bhatambre GS. Prevalence of TEM, SHV, and CTX-M Beta-Lactamase genes in the urinary isolates of a tertiary care hospital. Avicenna J Med. 2017;7(1):12.
7. Page M. Extended-spectrum β-lactamases: structure and kinetic mechanism. Clin Microbiol Infect. 2008;14(1):63–74.
8. Sharma J, Sharma M, Ray P. Detection of TEM & SHV genes in Escherichia coli & Klebsiella pneumoniae isolates in a tertiary care hospital from India. Indian J Med Res. 2010;131:3232–6.
9. Sharma M, Pathak S, Srivastava P. Prevalence and antibioticogram of Extended Spectrum β-Lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producing Escherichia coli and Klebsiella spp. J Clin Diagn Res. 2013;7(10):2173.
10. Dallenne C, Costa A, Decré D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important β-lactamases in Enterobacteriaceae. J Antimicrob Chemother. 2010;65(3):490–5.
11. Song J-H, Jung S-I, Ko KS, Kim NY, Son JS, Chang HH, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother. 2004;48(6):2101–7.
12. Hseuh PR, Hoban DJ, Carmeli Y, Chen SY, Desikan S, Alejandra M, et al. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Inf Secur. 2011;63(2):114–23.
13. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791.
14. Jean S-S, Hseuh PR. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents. 2011;37(4):291–5.
15. Kucheria R, Dasgupta P, Sacks S, Khan M, NJPmj S. Urinary tract infections: new insights into a common problem. Postgrad Med J. 2005;81(952):83–6.
16. Abrar S, Vajeeha A, Ul-Ain N, Riaz S. Distribution of CTX-M group I and group III β-lactamases produced by Escherichia coli and Klebsiella pneumoniae in Lahore, Pakistan. Microb Pathog. 2017;103:12–8.
17. Ejaz H. Detection of extended-spectrum β-lactamases in Klebsiella pneumoniae: Comparison of phenotypic characterization methods. Pak J Med Sci. 2013;29(3):768.
18. Jabeen K, Zafar A, RajoPMA H. Frequency and sensitivity pattern of extended spectrum beta lactamase producing isolates in a tertiary care hospital laboratory of Pakistan. J Pak Med Assoc. 2005;55(10):436.
19. Khan E, Ejaz M, Zafar A, Jabeen K, Shakoor S, Inayat R, et al. Increased isolation of ESBL producing Klebsiella pneumoniae with emergence of carbapenem resistant isolates in Pakistan: report from a tertiary care hospital. J Pak Med Assoc. 2010;60(3):186.
20. Abrar S, Hussain S, Khan RA, Ain NU, Haider H, Riaz S. Prevalence of extended-spectrum β-lactamase-producing Enterobacteriaceae: first systematic meta-analysis report from Pakistan. Antimicrob Resist Infect Control. 2018;7(1):26.
21. Muntaaz S, Ahmed J, Ali L, Hussain H. Prevalence of extended spectrum beta lactamases (ESBL) in clinical isolates from a teaching hospital in Peshawar, Pakistan. Afr J Microbiol Res. 2011;5(19):2880–4.
22. Vernet G, Mary C, Altmann DM, Dournoo O, Morpeth S, Bhutta ZA, et al. Surveillance for antimicrobial drug resistance in under-resourced countries. Emerg Infect Dis. 2014;20(5):343.
23. Bhardwaj AK, Vinothkumar K. Evolution of MDRs. Quorum Sensing vs Quorum Quenching: A Battle with No End in Sight. India: Springer, 2015. p. 9–22.
24. LS Cal. Performance standards for antimicrobial disk susceptibility testing: approved standard. Nati Comm Clin Lab Stand. 2014;6:285–9.
